Last update 01 Nov 2024
BEBT-209
Last update 01 Nov 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism CDK4 inhibitors(Cyclin-dependent kinase 4 inhibitors), CDK6 inhibitors(Cyclin-dependent kinase 6 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
9
Clinical Trials associated with BEBT-209BEBT-209联合系统化疗治疗晚期三阴性乳腺癌（TNBC）的II期临床试验
[Translation] Phase II clinical trial of BEBT-209 combined with systemic chemotherapy in the treatment of advanced triple-negative breast cancer (TNBC)
A Multicenter, Randomized, Controlled, Double-Blind Phase III Study of BEBT-209 in Combination with Fulvestrant Versus Placebo in Combination with Fulvestrant for the Treatment of HR-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Have Progressed on Prior Endocrine Therapy
一项随机、双盲、多中心、安慰剂对照的III期临床研究，评估BEBT-209联合氟维司群治疗HR阳性，HER2阴性晚期乳腺癌患者的有效性和安全性
[Translation] A randomized, double-blind, multicenter, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of BEBT-209 combined with fulvestrant in the treatment of patients with HR-positive, HER2-negative advanced breast cancer
100 Clinical Results associated with BEBT-209
Login to view more data
100 Translational Medicine associated with BEBT-209
Login to view more data
100 Patents (Medical) associated with BEBT-209
Login to view more data
100 Deals associated with BEBT-209
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hormone receptor positive HER2 negative breast cancer | Phase 3 | CN | 23 May 2022 | |
| Advanced Triple-Negative Breast Carcinoma | Phase 2 | CN | 03 Apr 2023 | |
| Advanced breast cancer | Phase 1 | CN | 15 Jul 2019 | |
| Estrogen receptor positive breast cancer | Phase 1 | CN | 15 Jul 2019 | |
| HER2-negative breast cancer | Phase 1 | CN | 15 Jul 2019 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free